Penicillin-Susceptible Streptococcus pneumoniae Meningitis in Adults: Does the Ceftriaxone Dosing Matter?
暂无分享,去创建一个
E. Barreto | S. Leib | A. Endimiani | P. Sendi | R. Baldan | A. Tande | Carlo Casanova | Urs Fischer | Samuel Raemy | U. Fischer
[1] G. Joynt,et al. Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients , 2022, Antimicrobial agents and chemotherapy.
[2] D. Marriott,et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper# , 2020, Intensive Care Medicine.
[3] V. Sébille,et al. High-Dose Ceftriaxone for Bacterial Meningitis and Optimization of Administration Scheme Based on Nomogram , 2019, Antimicrobial Agents and Chemotherapy.
[4] D. Boutoille,et al. CSF concentration of ceftriaxone following high-dose administration: pharmacological data from two French cohorts. , 2019, The Journal of antimicrobial chemotherapy.
[5] R. Heyderman,et al. Acute bacterial meningitis in adults , 2016, The Lancet.
[6] C. Whitney,et al. Community-acquired bacterial meningitis , 2016, Nature Reviews Disease Primers.
[7] K. Mühlemann,et al. Serotype/serogroup-specific antibiotic non-susceptibility of invasive and non-invasive Streptococcus pneumoniae, Switzerland, 2004 to 2014. , 2016, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[8] B. Mourvillier,et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[9] B. Salzberger,et al. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. , 2015, British journal of clinical pharmacology.
[10] A. van der Ende,et al. Epidemiology of invasive meningococcal disease in the Netherlands, 1960-2012: an analysis of national surveillance data. , 2014, The Lancet. Infectious diseases.
[11] S. Rulisa,et al. A comparison of the pharmacokinetics of Aspen Ceftriaxone and Rocephin in community-acquired meningitis. , 2013, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[12] Diederik van de Beek,et al. Pathogenesis and Pathophysiology of Pneumococcal Meningitis , 2011, Clinical Microbiology Reviews.
[13] F. Sörgel,et al. Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections , 2010, Clinical Microbiology Reviews.
[14] V. Buchta,et al. [Penetration of ceftriaxone into the cerebrospinal fluid and its relationship to inflammatory markers during bacterial meningitis]. , 2010, Klinicka mikrobiologie a infekcni lekarstvi.
[15] O. Sipahi,et al. Pooled Analysis of 2,408 Cases of Acute Adult Purulent Meningitis from Turkey , 2007, Medical Principles and Practice.
[16] Ronald N. Jones,et al. Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae. , 2007, Diagnostic microbiology and infectious disease.
[17] Wouter A Dreschler,et al. Dexamethasone and long‐term outcome in adults with bacterial meningitis , 2006, Annals of neurology.
[18] T. Poll,et al. Pneumococcal meningitis in adults: new approaches to management and prevention , 2006, The Lancet Neurology.
[19] J. Reitsma,et al. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series , 2006, The Lancet Neurology.
[20] Martijn Weisfelt,et al. Clinical features and prognostic factors in adults with bacterial meningitis. , 2004, The New England journal of medicine.
[21] H. Pfister,et al. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. , 2003, Brain : a journal of neurology.
[22] C. Çavuşoğlu,et al. Does dexamethasone affect ceftriazone penetration into cerebrospinal fluid in adult bacterial meningitis , 2003 .
[23] H. Pfister,et al. Pathogenesis and pathophysiology of pneumococcal meningitis. , 2002, The Lancet. Infectious diseases.
[24] B. Schmand,et al. Cognitive impairment in adults with good recovery after bacterial meningitis. , 2002, The Journal of infectious diseases.
[25] I. Lutsar,et al. Pharmacokinetics and Pharmacodynamics of Cephalosporins in Cerebrospinal Fluid , 2000, Clinical pharmacokinetics.
[26] C. Cabellos,et al. A single daily dose of ceftriaxone for bacterial meningitis in adults: experience with 84 patients and review of the literature. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] I. Bekersky,et al. Plasma protein binding of ceftriaxone. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.
[28] R. Spector. Ceftriaxone pharmacokinetics in the central nervous system. , 1986, The Journal of pharmacology and experimental therapeutics.
[29] J. Lefrock,et al. Diffusion of ceftriaxone into the cerebrospinal fluid of adults. , 1984, The Journal of antimicrobial chemotherapy.
[30] Jonathan,et al. Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults , 1982, Antimicrobial Agents and Chemotherapy.
[31] Jerome J. Schentag,et al. Clinical Use of Ceftriaxone , 2001, Clinical pharmacokinetics.